T1	PrimaryOutcome 48 63	clinical status
T2	TimeFrame 73 82	on day 14
T3	OutcomeDefinition 83 735	on a 7-point ordinal scale consisting of the following categories: 1, death; 2, hospitalized, receiving invasive mechanical ventilation or ECMO; 3, hospitalized, receiving noninvasive ventilation or high-flow oxygen devices; 4, hospitalized, requiring low-flow supplemental oxygen; 5, hospitalized, not requiring supplemental oxygen but receiving ongoing medical care (related or not related to Covid-19); 6, hospitalized, requiring neither supplemental oxygen nor ongoing medical care (other than that specified in the protocol for remdesivir administration); and 7, not hospitalized (see Table S1 in the Supplementary Appendix, available at NEJM.org)
R1	DefinedAs Arg1:T1 Arg2:T3	
T4	SecondaryOutcome 783 880	proportion of patients with adverse events that occurred on or after the first dose of remdesivir
T5	TimeFrame 881 918	for up to 30 days after the last dose
R2	MeasuredAt Arg1:T4 Arg2:T5	
T6	OtherOutcome 969 997	time to clinical improvement
T7	OutcomeDefinition 1010 1088	an improvement of at least 2 points from baseline on the 7-point ordinal scale
R3	DefinedAs Arg1:T6 Arg2:T7	
T8	OtherOutcome 1095 1111	time to recovery
T9	OutcomeDefinition 1113 1260	defined by the National Institute of Allergy and Infectious Diseases [NIAID] as an improvement from a baseline score of 2 to 5 to a score of 6 or 7
R4	DefinedAs Arg1:T8 Arg2:T9	
T10	OtherOutcome 1267 1292	time to modified recovery
T11	OutcomeDefinition 1305 1414	an improvement from a baseline score of 2 to 4 to a score of 5 to 7 or from a score of 5 to a score of 6 or 7
R5	DefinedAs Arg1:T10 Arg2:T11	
T12	OtherOutcome 1421 1441	death from any cause
